These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 25304342)
1. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study. Di Rienzo V; Cadario G; Grieco T; Galluccio AG; Caffarelli C; Liotta G; Pecora S; Burastero SE Ann Allergy Asthma Immunol; 2014 Dec; 113(6):671-673.e1. PubMed ID: 25304342 [No Abstract] [Full Text] [Related]
2. The relationship between total serum IgE levels and atopic sensitization in subjects with or without atopic dermatitis. Potaczek DP; Nasta Ek M; Wojas-Pelc A; Undas A Allergol Int; 2014 Sep; 63(3):485-6. PubMed ID: 24851947 [No Abstract] [Full Text] [Related]
3. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947 [TBL] [Abstract][Full Text] [Related]
4. The effectiveness of sublingual immunotherapy for house dust mite-induced allergic rhinitis and its co-morbid conditions. Chan AW; Luk WP; Fung LH; Lee TH Immunotherapy; 2019 Nov; 11(16):1387-1397. PubMed ID: 31608757 [No Abstract] [Full Text] [Related]
5. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites. Maloney J; Prenner BM; Bernstein DI; Lu S; Gawchik S; Berman G; Kaur A; Li Z; Nolte H Ann Allergy Asthma Immunol; 2016 Jan; 116(1):59-65. PubMed ID: 26553448 [TBL] [Abstract][Full Text] [Related]
6. Drugs for allergic disorders. Med Lett Drugs Ther; 2017 May; 59(1520):71-80. PubMed ID: 28463950 [No Abstract] [Full Text] [Related]
7. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432 [TBL] [Abstract][Full Text] [Related]
9. Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice. Tauber M; Apoil PA; Richet C; Laurent J; De Bonnecaze G; Mouchon E; Cassagne M; Marguery MC; Hegazy S; Konstantinou MP; Severino M; Uthurriague C; Giordano-Labadie F; Didier A; Paul C Br J Dermatol; 2019 Jun; 180(6):1551-1552. PubMed ID: 30633329 [No Abstract] [Full Text] [Related]
10. New developments in allergen immunotherapy. Vadlamudi A; Shaker M Curr Opin Pediatr; 2015 Oct; 27(5):649-55. PubMed ID: 26241500 [TBL] [Abstract][Full Text] [Related]
11. Association of early viral lower respiratory infections and subsequent development of atopy, a systematic review and meta-analysis of cohort studies. Kenmoe S; Kengne-Nde C; Modiyinji AF; Bigna JJ; Njouom R PLoS One; 2020; 15(4):e0231816. PubMed ID: 32330171 [TBL] [Abstract][Full Text] [Related]
12. Evaporative coolers are not associated with dust mite or mold sensitization in a large pediatric cohort. Izadi N; Brar KK; Lanser BJ Ann Allergy Asthma Immunol; 2018 May; 120(5):542-543. PubMed ID: 29481887 [No Abstract] [Full Text] [Related]
13. Association of atopy, asthma, allergic rhinoconjunctivitis, atopic dermatitis and intestinal helminth infections in Cuban children. Wördemann M; Diaz RJ; Heredia LM; Collado Madurga AM; Ruiz Espinosa A; Prado RC; Millan IA; Escobedo A; Rojas Rivero L; Gryseels B; Gorbea MB; Polman K Trop Med Int Health; 2008 Feb; 13(2):180-6. PubMed ID: 18304263 [TBL] [Abstract][Full Text] [Related]
14. Rare adverse events due to house dust mite sublingual immunotherapy in pediatric practice: two case reports. Galip N; Bahceciler N Immunotherapy; 2015; 7(12):1235-9. PubMed ID: 26427747 [TBL] [Abstract][Full Text] [Related]
16. Changes in inflammatory and clinical parameters and in bronchial hyperreactivity asthmatic children sensitized to house dust mites following sublingual immunotherapy. Silvestri M; Spallarossa D; Battistini E; Sabatini F; Pecora S; Parmiani S; Rossi GA J Investig Allergol Clin Immunol; 2002; 12(1):52-9. PubMed ID: 12109533 [TBL] [Abstract][Full Text] [Related]
17. Phase I study of subcutaneous allergen immunotherapy with Dermatophagoides pteronyssinus in patients with allergic rhinoconjunctivitis with or without asthma. Hernández Fernández de Rojas D; Antépara Ercoreca I; Ponte Tellechea A; Ibáñez Echevarría E; Jáuregui Presa I; Gamboa Setién P; Asturias JA; Landeta Manzano A; Madariaga Goirigolzarri B Immunotherapy; 2015; 7(2):89-99. PubMed ID: 25659029 [TBL] [Abstract][Full Text] [Related]
19. Randomized double-blind placebo-controlled trial of sublingual immunotherapy in children with house dust mite allergy in primary care: study design and recruitment. de Bot CM; Moed H; Berger MY; Röder E; de Groot H; de Jongste JC; van Wijk RG; van der Wouden JC BMC Fam Pract; 2008 Oct; 9():59. PubMed ID: 18937864 [TBL] [Abstract][Full Text] [Related]
20. Induction of remission of idiopathic anaphylaxis with rituximab. Borzutzky A; Morales PS; Mezzano V; Nussbaum S; Burks AW J Allergy Clin Immunol; 2014 Oct; 134(4):981-3. PubMed ID: 25018095 [No Abstract] [Full Text] [Related] [Next] [New Search]